You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on colorectal cancer.
Researchers at MD Anderson Cancer Center found that somatic copy number alterations are more frequent in normal tissue surrounding tumor than in blood.
The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 89 percent year over year.
In PLOS this week: RAPGEF6 gene insertion linked to laryngeal paralysis in Miniature Bull Terriers, colorectal cancer risk among Zimbabweans, and more.
Although normal tissues with somatic mutations did not necessarily progress to cancer, researchers saw a jump in mutational burden in samples associated with cancer or cirrhosis.
New Horizon Health's test, ColoClear, is a stool-based DNA test specifically designed to detect colon cancer in individuals of Asian descent.
Circulating tumor DNA detection in stage III colon cancer patients after surgery and adjuvant chemotherapy coincided with a rise in recurrence risk.
Hatched from the computational genomics lab at Ghent University, BioLizard offers a small but complementary team to tackle AI and molecular pipeline challenges.
The Voyage study is designed to enroll more than 150,000 people and will follow participants for at least seven years.
The seven-gene test, ColonSentry, is designed to determine an individual's current risk for colorectal cancer relative to an average risk population.
NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.
Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.
A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.
In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.